Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

414 sites for NCT02339571

BRAF Mutation

Melanoma

ipilimumab, +2 more drugs

immunotherapy, +1 more type

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

23 sites for NCT04488003

BRAF Codon 469 Missense, +16 more biomarkers

Colorectal Carcinoma, +1 more condition

ulixertinib

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

1 site for NCT05168904

BRAF Mutation, +6 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

CYC065

targeted therapy

A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer

34 sites for NCT04620330

BRAF Mutation, +1 more biomarker

Non-Small Cell Lung Carcinoma

defactinib, +1 more drug

targeted therapy

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

4 sites for NCT05054374

ARAF Mutation, +18 more biomarkers

Breast Carcinoma, +1 more condition

fulvestrant, +1 more drug

hormone therapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab

3 sites for NCT05121038

BRAF Mutation, +3 more biomarkers

Appendix Adenocarcinoma, +2 more conditions

CEND-1, +2 more drugs

chemotherapy, +1 more type

Study of ASTX029 in Subjects With Advanced Solid Tumors

15 sites for NCT03520075

ARAF Mutation, +16 more biomarkers

Malignant Solid Tumor

ASTX029

targeted therapy